The executive director of Health Services and Benefits of the Social Security Fund (CSS), Alex González has told the institutional directors, hospitals, polyclinics and other care units of the entity to make sure that the health facility "does not prescribe" Ivermectin and Hydroxychloroquine for the management of patients with Covid-19.

"Clinical trials carried out in hospitalized and outpatients with Covid-19 did not determine therapeutic efficacy with the use of Hydroxychloroquine and Ivermectin or reduction in mortality and severity of the disease and, until more data is available, the World Organization for Health recommends using this drug only in clinical trials ”, indicated González.

In the circular, it is noted that the use of these two products in particular has been associated with serious adverse events related to heart rhythm.

"In light of the available scientific evidence, Hydroxychloroquine and Ivermectin should not be used for the treatment or prevention of Covid-19," the official said.

Ivermectin is a drug used in humans and animals. The US Food and Drug Administration has approved this drug in humans for head infections caused by some worms, parasites, and lice, as well as skin conditions such as rosacea.

Meanwhile, Hydroxychloroquine is also used to prevent and treat acute attacks of malaria; to treat discoid lupus erythematosus (a chronic inflammatory condition of the skin) or systemic lupus erythematosus (a chronic inflammatory condition of the body); and for rheumatoid arthritis in patients whose symptoms do not improve with other treatments.